After Re-examination, CHMP Recommends Approval of DAYBU for Rett Syndrome in the EU
Acadia’s DAYBU gets EU positive opinion for Rett syndrome; could become first approved treatment for symptoms in Europe.
/ 1648 items
#XY↓
Rademikibart Breakthrough Potential: Piper Sandler Sees First-in-Class Opportunity at CNTB
Rademikibart offers first-mover potential in acute asthma & COPD with major Phase 2 data coming in September 2026.
Jefferies Upgrades Tango Therapeutics to Buy, Lifts Price Target to $60 on Promising Pancreatic Cancer Data
Jefferies turned bullish on Tango Therapeutics as early cancer data and big market potential lifted its price target.
Tempus AI Shares Rise on New Angiosarcoma Research Collaboration
Tempus AI announces research collaboration with Angiosarcoma Awareness, analyzing ~600 patient records with paired DNA/RNA data to accelerate rare cancer insights.
ARS Pharmaceuticals Shares Plunge as Neffy Misses July Insurance Wins
Despite the setback, Florida Medicaid coverage begins July 1, the company cut 2026 expenses to $248M, and it remains on track for cash-flow breakeven in 2027.
Merck KGaA Bolsters Life Sciences Portfolio with $11.3B Bio-Techne Acquisition
Acquisition of a medical tools maker will be the German group’s biggest in over a decade.